Table S1 The primers for qPCR used in RNA-ChIP and Chip

Predicted Target Region	Forward Primers(5'-3')	Reverse Primers(5'-3')
A	GAGGTTTTTCAGGGGGAGAC	AAGGGCTGAGATAGGGAGGA
B	GGTTTTGGGGAGGAAGTGAG	CCGCTCATCGTAGAGGAAAC
C	TCTGTGAAGATGGCATGGTG	CCTGGAAGCACTTTCTTGGA
D	CTGCTCCGTCTTAGCATTCC	CTCCCCAAATGGTGTCTGTC
E	GCACAGGAATGACAGACACC	AGCACAGCACCCAAAGAAGT
F	TGGATGCTAAGTCCAGTTTTCA	TGACCTTAGCTCCATCCTTGA
G	TCAAGGATGGAGCTAAGGTCA	AACGTCCCCTGCTTTTCTCT
a	AAATAAGCAGGGTGCAGTGG	AGAGACAGGGTCTGGCTTTG
b	TTCTGTAGGGCAACGGCTAT	CCAGCTGTTTTCTGCGAAGT
c	GGGAGAGGGAATTCAAACCT	AGAGGGCAAAGGTGATGCTA
d	CGGGACTTGCAGTCTTTCAT	GGGATGAATTTGAGCTGACG
e	CCTTCCGTCAGCTCAAATTC	AGGGCCAAGGGAACTACAAC
f	GAGGTTTTTCAGGGGGAGAC	AAGGGCTGAGATAGGGAGGA



Supplemental Fig.1. (A), Chemical structure of compound JL014; (B), HUVECs were treated with 1μM, 5 μM, 10 μM or 20μM JL014 in basal M199 medium with serum and FGF-2 deprivation for 12 h; (C), HUVECs were pretreated with10 mM 3MA for 6 h and then were treated with 10 μM JL014; (D), HUVECs were treated with 60 nM ATG5 siRNA or scramble siRNA for 24 h and stimulated with 10 μM JL014 for up to 24 h. Cell viability was analyzed by SRB assay. *$p < 0.05$, **$p < 0.01$.



Supplemental Fig.2. (A), Six binding sites (a-f) 2-kb upstream of the *HMBOX1* promoter region were analysed in ChIP experiments; (B), HUVECs were treated with or 10 μM JL014 for 3 h and submitted to ChIP-qPCR analysis. (C), Seven regions (A–G) across *HMBOX1* 5'UTR and 3'UTR were analysed in RNA-ChIP experiments; (D), HUVECs were treated with or 10 μM JL014 for 3 h and submitted to RNA-ChIP-qPCR analysis.